Clinical trials: Cancer Pelvis
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Glycoprotein and Glycan in Tissue and Blood Samples of Patients With Stage IB-IVA Cervical Cancer Undergoing Surgery to Remove Pelvic and Abdominal Lymph Nodes
This clinical trial studies glycoprotein and glycan in tissue and blood samples of patients with stage IB-IVA cervical cancer undergoing surgery to remove pelvic and abdominal lymph nodes.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Small Cell Carcinoma, Cervical Squamous Cell Carcinoma, Not Otherwise Specified
- Trial name
- NCT00460356
- Testing
- Laboratory Biomarker Analysis, Lymphadenectomy
- Where
- 18 sites in United States
- Volunteers
- 159 people
- Sponsor
- Gynecologic Oncology Group
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Combination Chemotherapy in Treating Patients With Metastatic or Locally Advanced Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003105
- Testing
- filgrastim, cisplatin, doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Magnetic Resonance Imaging
Gadobutrol Magnevist-controlled Body Study
The purpose of the study is to look at the safety (what are the side effects) and efficacy (how well does it work) of gadobutrol when used for taking MR images of the body/extremities regions.
- Trial name
- NCT01050829
- Testing
- Gadobutrol (Gadovist, BAY86-4875), Gadopentetate Dimeglumine (Magnevist, BAY86-4882)
- Where
- 15 sites in China, Japan and 1 more
- Volunteers
- 370 people
- Sponsor
- Bayer
Cancer
Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients
RATIONALE: Palliative care may help patients with advanced cancer live more comfortably. PURPOSE: This randomized clinical trial is studying an early intervention palliative care program to see how well it works compared to a…
- Trial name
- NCT00253383
- Testing
- counseling intervention, educational intervention, psychosocial assessment and care
- Where
- 2 sites in United States
- Volunteers
- 329 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Sarcoma
Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Giving radiation therapy before surgery may shrink the tumor so that it can be removed.
- Trial name
- NCT00091351
- Testing
- conventional surgery, radiation therapy
- Where
- 59 sites in United States, Canada
- Volunteers
- 370 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Prostate Cancer
Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])
This is an open-label, nonrandomized, multicenter study conducted in two sequential parts: an initial Phase 2 Dose Optimization Period followed by the Phase 3 Diagnostic Performance Period.
- Trial name
- SPARROW (NCT07831824)
- Testing
- [68Ga]-LNTH-2401
- Where
- United States
- Volunteers
- 408 people
- Sponsor
- Lantheus Medical Imaging
Colo-rectal Cancer
EMVI as a Determinant of Metastasis in Colorectal Cancer
Bowel cancer is the fourth most commonly occurring cancer and the second highest cause of cancer deaths in the UK. Despite advances in treatment, over 40% of patients will die within 5 years.
- Trial name
- EVIDENCE (NCT06646341)
- Where
- United Kingdom
- Volunteers
- 100 people
- Sponsor
- Imperial College London
Total Exenteration, Anterior or Posterior Pelvic Exenteration
Quality of Life in Patients Undergoing Total Pelvic Exenteration
The purpose of this study is to learn more about the personal experiences of patients who are treated with pelvic exenteration surgery.
- Conditions
- Total Exenteration, Anterior or Posterior Pelvic Exenteration, Gynecologic Malignancies, Colorectal Malignancies
- Trial name
- NCT00597805
- Testing
- questionnaires/interviews
- Where
- 8 sites in United States
- Volunteers
- 94 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Polycystic Ovarian Syndrome, Pelvic Endometriosis
Prevalence of HbA1C in Women With PCOS
Women with PCOS have been observed to be potential diabetics.Recently,American Diabetes Association has suggested screening of women with PCOS for HbA1C.
- Conditions
- Polycystic Ovarian Syndrome, Pelvic Endometriosis, Insulin Resistance, Non-insulin Dependent Diabetes Mellitus
- Trial name
- WHI (NCT01838122)
- Where
- India
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Southern Cross Fertility Centre
Benign, Premalignant and Malignant Gynecological Disease Confined to the Pelvis
Teleassisted Surgery for Gynecological Disease in Obese Patients - OB-ALFX
Phase II prospective single-institutional study.
- Trial name
- OB-ALFX (NCT02338505)
- Testing
- Telelap ALF-X
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- Catholic University of the Sacred Heart
Uterine Cervical Neoplasms
Pelvic IMRT With Tomotherapy: A Phase I Feasibility Study in Post-Hysterectomy Cervical Cancer Patients
Indications for post-hysterectomy radiation therapy (RT) have been well established by clinical data. Adjuvant RT has demonstrated local control and survival benefit.
- Trial name
- NCT00359866
- Testing
- IMRT with tomotherapy
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Washington University School of Medicine
Uterine Cervix Cancer
A Study of Nelfinavir Added to Cisplatin Chemotherapy Concurrent With Pelvic Radiation for Locally Advanced Cervical Cancer (II-IVA)
Patients 18 years of age and older with clinical stages IIA, IIB, IIIA, IIIB, IVA cervical carcinoma limited to the pelvis will receive twice daily oral nelfinavir (NFV) and weekly IV cisplatin in combination as radiosensitizers…
- Trial name
- NCT02363829
- Testing
- Nelfinavir, Cisplatin
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Myeloproliferative Disorder, Urothelial Carcinoma
Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma
Gemcitabine and carboplatin are two standard chemotherapy drugs used to treat tumors of the urothelial tract. These drugs do not shrink tumors in all patients and when they do, it is generally for a limited amount of time.
- Conditions
- Myeloproliferative Disorder, Urothelial Carcinoma, Cancer
- Trial name
- NCT00588666
- Testing
- Bevacizumab, Carboplatin, Gemcitabine
- Where
- 6 sites in United States
- Volunteers
- 51 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Prostate Cancer Surgery, Prostate Cancers
Extended vs. No Pelvic Lymph Node Dissection During Radical Prostatectomy. DISSECTION 2.0.
The aim of the DISSECTION 2.0 study is to determine whether extended pelvic lymph node dissection (ePLND) provides a therapeutic benefit for high-risk prostate cancer patients by improving cancer staging and potentially removing…
- Trial name
- NCT06776172
- Testing
- Extended Pelvic Lymph Node Dissection
- Where
- 15 sites in Switzerland
- Volunteers
- 400 people
- Sponsor
- University Hospital, Basel, Switzerland
Bladder Cancer, Urothelial Carcinoma
Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma
The purpose of the ATLAS study is to determine how patients with locally advanced unresectable or metastatic urothelial carcinoma respond to treatment with rucaparib.
- Conditions
- Bladder Cancer, Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Renal Pelvis Carcinoma
- Trial name
- ATLAS (NCT03397394)
- Testing
- Rucaparib
- Where
- 64 sites in United States, France and 4 more
- Volunteers
- 97 people
- Sponsor
- pharmaand GmbH
Rectal Cancer
"Impact of Pelvic Floor Prehabilitation Using Biofeedback on the Severity of the Low Anterior Resection Syndrome in Patients Undergoing a Total Mesorectal Excision for Rectal Cancer"
There is currently no specific treatment and only few measures to prevent the low anterior resection syndrome (LARS). The LARS often results in a severe alteration of quality of life.
- Trial name
- CONTICARE (NCT03876561)
- Testing
- Pelvic floor prehabilitation
- Where
- 6 sites in France
- Volunteers
- 120 people
- Sponsor
- Nantes University Hospital
Pelvic Neoplasm
Exploiting the Gut Microbiota and Its Metabolites in Pelvic Cancer
The large intestine is the last part of the digestive tract. It absorbs water and dietary substances. However, it is also where most of our bacteria are resident.
- Trial name
- NCT05605353
- Testing
- Faecal microbiota sampling and blood sampling
- Where
- United Kingdom
- Volunteers
- 450 people
- Sponsor
- University of Aberdeen
Pelvic Cancer, Enteritis, Probiotics,Chemoradiotherapy
Oral Probiotics on Radiation Enteritis Stage Ⅱ Induced by Pelvic Concurrent Chemoradiotherapy
Effect of Probiotics on Raditon Enteritis in Pelvic Tumor Patients Receiving Radiotherapy.
- Trial name
- probiotics (NCT05032027)
- Testing
- probiotics
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Jiangxi Provincial Cancer Hospital
Oligometastatic Hormone-Sensitive Prostate Cancer, Prostate Adenocarcinoma
Prospective Study on the Role of Radical Prostatectomy in Oligo-metastatic Hormone-sensitive Prostate Cancer in Patients on Androgen Deprivation Therapy
MAZINGA is a prospective, single-group pilot study evaluating disease control after robot-assisted radical prostatectomy with extended pelvic lymph-node dissection in men with oligometastatic hormone-sensitive prostate…
- Trial name
- MAZINGA (NCT07766486)
- Testing
- Robot-Assisted Radical Prostatectomy With Extended Pelvic Lymph-Node Dissection
- Where
- Italy
- Volunteers
- 30 people
- Sponsor
- Fondazione del Piemonte per l'Oncologia
Cervical Carcinoma
Systemic and Tumor Immune Response During Pelvic (Chemo)Radiation and/or Brachytherapy for Cervical Cancer
Radiotherapy result in tumor cell death by creating an immune potentiation effect, but can also lead to long lasting immune suppression.
- Trial name
- STIRR (NCT06804135)
- Where
- India
- Volunteers
- 110 people
- Sponsor
- Tata Memorial Hospital